Kazia Therapeutics Enterprise value
What is the Enterprise value of Kazia Therapeutics?
The Enterprise value of Kazia Therapeutics Limited is $3.91M
What is the definition of Enterprise value?
Enterprise value is a measure of a company’s total market value. It is calculated as market capitalization with debt, minority interest, and preferred shares minus total cash and cash equivalents.
ttm (trailing twelve months)
It is a sum of claims by all claimants including creditors (secured and unsecured) and shareholders (preferred and common). Enterprise value is one of the fundamental metrics used in business valuation, financial modeling, accounting, portfolio analysis, and risk analysis. Enterprise value is more comprehensive than market capitalization, which only reflects common equity and is considered more representative of a company’s value. Enterprise value reflects the opportunistic nature of business and may change substantially over time because of both external and internal conditions.
Enterprise value can be negative if the company holds abnormally high amounts of cash that is not reflected in the market value of the stock and total capitalization. Cash is subtracted in the calculation because it reduces the net cost to a potential purchaser. The effect applies whether the cash is used to issue dividends or to pay down debt. Value of minority interest is added because it reflects the claim on assets consolidated into the firm in question. Value of associate companies is subtracted because it reflects the claim on assets consolidated into other firms. EV should also include such special components as unfunded pension liabilities, employee stock options, environmental provisions, abandonment provisions, and so on, since they also reflect claims on the company.
Enterprise value of companies in the Health Care sector on ASX compared to Kazia Therapeutics
What does Kazia Therapeutics do?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Companies with enterprise value similar to Kazia Therapeutics
- Neovasc has Enterprise value of $3.90M
- Lypsa Gems & Jewellery has Enterprise value of $3.90M
- Personas Social has Enterprise value of $3.90M
- Taura Gold Inc has Enterprise value of $3.90M
- Honey Badger Exploration has Enterprise value of $3.90M
- Golden Minerals Co has Enterprise value of $3.91M
- Kazia Therapeutics has Enterprise value of $3.91M
- Magnolia Colombia has Enterprise value of $3.91M
- Highway 50 Gold has Enterprise value of $3.91M
- Cellmid has Enterprise value of $3.92M
- Pancontinental Resources has Enterprise value of $3.92M
- ParcelPal Technology has Enterprise value of $3.92M
- Onelife Capital Advisors has Enterprise value of $3.93M